Suppliers and packagers for HEPARIN SODIUM

HEPARIN SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Be Pharms	HEPARIN SODIUM	heparin sodium	INJECTABLE;INJECTION	214804	ANDA	BE Pharmaceuticals Inc.	71839-117-25	25 VIAL, SINGLE-DOSE in 1 CARTON (71839-117-25) / 2 mL in 1 VIAL, SINGLE-DOSE (71839-117-01)	2020-12-29
Be Pharms	HEPARIN SODIUM	heparin sodium	INJECTABLE;INJECTION	214839	ANDA	BE Pharmaceuticals Inc.	71839-118-25	25 VIAL, SINGLE-DOSE in 1 CARTON (71839-118-25) / .5 mL in 1 VIAL, SINGLE-DOSE (71839-118-01)	2020-12-29
Emerge Bioscience	HEPARIN SODIUM	heparin sodium	INJECTABLE;INJECTION	211005	ANDA	Meitheal Pharmaceuticals Inc.	71288-400-03	25 VIAL, SINGLE-DOSE in 1 CARTON (71288-400-03) / 2 mL in 1 VIAL, SINGLE-DOSE (71288-400-02)	2019-06-15
Emerge Bioscience	HEPARIN SODIUM	heparin sodium	INJECTABLE;INJECTION	211005	ANDA	NorthStar RxLLC	72603-336-25	25 VIAL, SINGLE-DOSE in 1 CARTON (72603-336-25) / 2 mL in 1 VIAL, SINGLE-DOSE (72603-336-01)	2024-04-01
Emerge Bioscience	HEPARIN SODIUM	heparin sodium	INJECTABLE;INJECTION	211007	ANDA	Meitheal Pharmaceuticals Inc.	71288-402-02	25 VIAL, SINGLE-DOSE in 1 CARTON (71288-402-02) / 1 mL in 1 VIAL, SINGLE-DOSE (71288-402-01)	2019-06-15

Heparin Sodium Supply Chain Analysis

Last updated: February 19, 2026

What is Heparin Sodium and Its Significance?

Heparin sodium is a critical anticoagulant medication used to prevent and treat blood clots. It is derived from animal tissue, primarily porcine intestinal mucosa, making its supply chain inherently vulnerable to animal health, sourcing regulations, and geopolitical factors. The drug's efficacy and widespread use in diverse medical settings, including surgery, dialysis, and critical care, underscore its importance in patient safety and public health.

Who are the Primary Manufacturers of Heparin Sodium API?

The production of heparin sodium Active Pharmaceutical Ingredient (API) is concentrated among a limited number of global suppliers. This concentration poses strategic risks and necessitates careful monitoring of production capacity and regulatory compliance.

• Key API Manufacturers:
  • Hepalink Group (China): A dominant player in the global heparin market, Hepalink is a major supplier of crude heparin and finished heparin sodium API. Its integrated supply chain extends from sourcing raw materials to API production.
  • Changshan Biochemical Pharmaceutical Co., Ltd. (China): Another significant Chinese manufacturer, Changshan is a key producer of heparin sodium API and low molecular weight heparin (LMWH) products.
  • PharmaDEX (Germany): This European producer focuses on high-quality heparin products, emphasizing strict regulatory adherence and advanced manufacturing processes.
  • Opocrin S.p.A. (Italy): An established manufacturer with a long history in heparin production, Opocrin supplies heparin sodium API to various global markets.
  • Scientific Protein Laboratories LLC (SPL) (USA): SPL is a US-based producer of heparin sodium API, serving the North American market and adhering to stringent FDA regulations.

What are the Raw Material Sourcing Challenges?

The primary raw material for heparin sodium is crude heparin, extracted from porcine intestinal mucosa. This dependence on animal-derived material introduces specific vulnerabilities.

• Geographic Concentration of Swine Population: A significant portion of the global swine population is concentrated in China, which directly impacts the availability and price of porcine intestinal mucosa.
• Animal Disease Outbreaks: Diseases such as African Swine Fever (ASF) can decimate swine populations, leading to severe shortages of raw material. ASF outbreaks in Asia have previously disrupted heparin supply chains.
• Religious and Cultural Factors: Certain cultural or religious practices in some regions may limit the availability of porcine-derived materials.
• Traceability and Quality Control: Ensuring the consistent quality and traceability of crude heparin from diverse sourcing locations is a complex undertaking, requiring robust supplier audits and testing protocols.
• Regulatory Scrutiny: Regulatory bodies worldwide, including the FDA and EMA, impose strict requirements on the sourcing and handling of animal-derived raw materials to prevent the transmission of infectious agents.

What is the Regulatory Landscape for Heparin Sodium?

The regulatory environment for heparin sodium is stringent due to its origin and critical therapeutic use. Compliance with pharmacopoeial standards and GMP (Good Manufacturing Practice) is mandatory.

• Key Regulatory Bodies:

  • U.S. Food and Drug Administration (FDA): The FDA regulates heparin sodium API and finished products sold in the United States. This includes inspections of manufacturing facilities, review of drug master files (DMFs), and adherence to current Good Manufacturing Practices (cGMP).
  • European Medicines Agency (EMA): The EMA oversees the approval and regulation of medicines in the European Union. Manufacturers must comply with EU GMP and European Pharmacopoeia (Ph. Eur.) standards.
  • National Medical Products Administration (NMPA) (China): The NMPA regulates pharmaceutical products in China, including those manufactured by Chinese heparin producers.
  • Other National Regulatory Authorities: Manufacturers must comply with the specific regulations of each country where their products are marketed.

• Pharmacopoeial Standards: Heparin sodium API must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define identity, purity, potency, and other critical quality attributes.

• Good Manufacturing Practices (GMP): Adherence to GMP is essential throughout the manufacturing process, from raw material sourcing to final API production. This ensures product quality, consistency, and safety.

• Chinese Government Policies: Chinese government policies related to animal health, environmental protection, and export controls can directly influence heparin supply and pricing. Recent crackdowns on environmental violations have led to plant closures and production disruptions for some Chinese manufacturers.

Who are the Major Suppliers of Heparin Sodium Finished Products?

Beyond API production, several companies formulate and manufacture finished dosage forms of heparin sodium. These companies rely on the API suppliers mentioned previously.

• Key Finished Product Manufacturers (Examples):
  • Pfizer Inc. (USA): Markets heparin sodium injections under various brand names, sourced from approved API manufacturers.
  • B. Braun Melsungen AG (Germany): A significant global supplier of injectable pharmaceuticals, including heparin sodium.
  • Fresenius Kabi AG (Germany): Offers a range of heparin products for medical use.
  • Leo Pharma (Denmark): While known for LMWH, Leo Pharma also has a presence in the broader heparin market.
  • Sanofi S.A. (France): A major pharmaceutical company that may have heparin products within its portfolio or through acquisitions.

What are the Market Dynamics and Pricing Factors?

The heparin sodium market is characterized by a delicate balance between supply and demand, heavily influenced by raw material availability and regulatory changes.

• Supply Vulnerabilities: The inherent reliance on porcine sources makes the supply chain susceptible to disruptions from disease outbreaks, trade policies, and raw material quality fluctuations.
• Demand Stability: Demand for heparin sodium is relatively stable due to its essential role in critical care and routine medical procedures. However, significant spikes can occur during pandemics or large-scale public health crises.
• Price Volatility: Historically, heparin prices have experienced significant volatility. For instance, the heparin crisis of 2008, caused by contamination issues originating from China, led to severe shortages and price surges, highlighting the market's fragility.
• Competition: While the number of API manufacturers is limited, competition exists among them. However, the high barriers to entry (regulatory approval, manufacturing expertise, sourcing relationships) limit new players.
• Geopolitical Influences: Trade tensions, tariffs, and export/import restrictions between major heparin-producing nations and consumer markets can impact pricing and availability.

What are the Risks and Mitigation Strategies for Pharmaceutical Companies?

Companies relying on heparin sodium face significant risks that require proactive management.

• Supply Chain Disruption:
  • Risk: Shortages due to animal disease, raw material quality issues, or geopolitical events.
  • Mitigation: Diversify API suppliers across different geographic regions. Establish long-term contracts with key suppliers. Maintain strategic inventory levels. Conduct rigorous due diligence and audits of all suppliers. Explore alternative sourcing options where feasible, though this is challenging for heparin.
• Regulatory Compliance:
  • Risk: Failure to meet evolving pharmacopoeial standards or GMP requirements, leading to product recalls or market withdrawal.
  • Mitigation: Implement robust quality management systems. Stay abreast of regulatory changes and pharmacopoeial updates. Invest in advanced analytical testing and process validation. Engage proactively with regulatory authorities.
• Price Volatility:
  • Risk: Unpredictable price increases impacting cost of goods sold.
  • Mitigation: Negotiate long-term pricing agreements with suppliers where possible. Monitor market trends and commodity prices. Explore cost-saving measures in manufacturing and logistics.
• Counterfeit and Substandard Products:
  • Risk: Introduction of adulterated or falsified heparin products into the supply chain, as seen in the 2008 crisis.
  • Mitigation: Implement stringent incoming raw material testing and finished product release testing. Enhance supply chain security and traceability measures. Collaborate with regulatory agencies and industry groups to combat counterfeiting.

What is the Future Outlook for Heparin Sodium Supply?

The future supply of heparin sodium will likely continue to be shaped by existing trends, with a focus on quality assurance and supply chain resilience.

• Increased Regulatory Oversight: Expect continued tightening of regulatory requirements globally, particularly concerning the sourcing and traceability of animal-derived materials.
• Consolidation: The market may see some consolidation among API suppliers as companies seek economies of scale and greater control over their supply chains.
• Technological Advancements: While a complete synthetic alternative to unfractionated heparin remains elusive, ongoing research into alternative anticoagulant mechanisms and improvements in manufacturing technologies could influence future supply dynamics.
• Focus on Traceability and Transparency: Pharmaceutical companies and regulatory bodies will increasingly demand greater transparency and traceability throughout the heparin supply chain, from the farm to the finished product.
• Potential for Alternative Sourcing: While challenging, research into alternative sources of heparin or heparin-like molecules may gain traction if supply chain vulnerabilities persist.

Key Takeaways

The heparin sodium supply chain is characterized by a high degree of concentration, reliance on animal-derived raw materials, and stringent regulatory oversight. Key risks include supply disruptions from animal diseases, geopolitical factors, and the potential for substandard products. Mitigation strategies must focus on supplier diversification, robust quality management, proactive regulatory engagement, and enhanced supply chain security.

Frequently Asked Questions

1. Are there any fully synthetic alternatives to heparin sodium currently approved for widespread clinical use? No, currently there are no fully synthetic alternatives approved that can fully replace unfractionated heparin sodium for all its indications.
2. What are the primary geographical regions for sourcing porcine intestinal mucosa? China is the largest single source of porcine intestinal mucosa globally, followed by other regions with significant pork production.
3. How frequently do regulatory agencies audit heparin API manufacturing facilities? Audit frequency varies by agency and manufacturer, but routine GMP inspections by the FDA and EMA typically occur every two to three years, with potential for unannounced inspections.
4. What is the typical shelf life of heparin sodium API and finished products? Heparin sodium API shelf life can range from 2 to 5 years when stored under recommended conditions, while finished injectable products typically have a shelf life of 18 to 36 months.
5. What measures are in place to prevent contamination events similar to the 2008 heparin crisis? Measures include enhanced raw material testing for specific contaminants, improved supplier qualification processes, increased regulatory oversight, and stricter adherence to GMP guidelines.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Heparin Information. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/heparin-information [2] European Medicines Agency. (n.d.). Products. Retrieved from https://www.ema.europa.eu/en/medicines [3] World Health Organization. (n.d.). Heparin. Retrieved from https://www.who.int/medicines/areas/quality_safety/drug_shortages/heparin_2008/en/ [4] Pharmaceutical Technology. (n.d.). Heparin Sodium API Manufacturers and Market Analysis. (Specific articles and reports from Pharmaceutical Technology often cover API supply chains. While a direct permanent link is not feasible, this denotes the type of industry publication where such data is found). [5] Fierce Pharma. (n.d.). Reports on Pharmaceutical Supply Chains and Regulatory Issues. (Similar to [4], Fierce Pharma is a key industry news source for this type of analysis).